Ongoing Clinical Trials

• A Study of LY3154207 in Participants With Parkinson's Disease Dementia (PRESENCE) (NCT03305809)
• Clinical Effect Durability of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure (NCT03829657)
• Wearable Assessments in the Clinic and Home in PD (WATCH-PD) (NCT03681015)

• Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3) Protocol (NCT02854033)
• A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease (NCT03443973)
• A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease (Clarity AD) (NCT03887455)

• Under Alzheimer's disease enrolling add NCT A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB) (PRESENCE) (NCT03305809)

The Brain and Body Donation Program

Study Goals: This study is designed to be able to compare the brain function of living adults with tissue that they donate when they pass away.

What’s Involved: Participants will be seen in person once per year to complete assessments of neurological and motor function, sense of smell, memory and thinking, sleep and general medical health. When participants pass away, a transport service will bring them to the Institute for autopsy. The tissues that they donate will be used to provide a diagnostic autopsy report and will be stored for future use by researchers locally and throughout the world to study aging, cancer, Parkinson’s and Alzheimer’s (as well as related conditions).

Eligible patients will:

• Have a diagnosis of Parkinson’s, Alzheimer’s disease, dementia with Lewy bodies or REM sleep behavior disorder
• Reside (at least 6 months per year) in Maricopa County
• Be willing to participate in annual assessments at the Institute    

To learn more contact us at (623) 832-6500.